| HOME >> BIOLOGY >> TECHNOLOGY |
Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: our HspE7 fusion protein's potential utility in individuals with compromised CD4+ functions.
Such forward-looking statements or information involve known and
unknown risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be materially
different from any future results, events or developments expressed or
implied by such forward-looking statements or information. Such factors
include, among others, our need for capital, risks associated with
requirements for approvals by government agencies such as the FDA before
products can be tested in clinical trials; the possibility that such
government agency approvals will not be obtained in a timely manner or at
all or will be conditioned in a manner that would impair our ability to
advance development; risks associated with the requirement that a drug be
found safe and effective after extensive clinical trials and the
possibility that the results of such trials, if commenced and completed,
will not establish the safety or efficacy of our products; our dependence
on suppliers, collaborative partners and other third parties and the
prospects and timing for negotiating supply agreements, corporate
collaborations or licensing arrangements; our ability to attract and retain
key personnel; our ability to protect and practice our intellec
'/>"/>
| SOURCE Nventa Biopharmaceuticals Corporation Copyright©2007 PR Newswire. All rights reserved |